Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joost P Hegmans

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cancer Research|April 13, 2013
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancerJoachim G Aerts, Joost P Hegmans
BMC Pulmonary Medicine|December 14, 2012
Improving lung cancer survival; time to move onMarlies E Heuvers, Joost P Hegmans, Bruno H Stricker, et al.
Translational Lung Cancer Research|March 26, 2015
Immunotherapy prospects in the treatment of lung cancer and mesotheliomaJoachim G Aerts, Lysanne A Lievense, Henk C Hoogsteden, et al.
BMC Cancer|December 11, 2012
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatmentMarlies E Heuvers, Joachim G Aerts, Robin Cornelissen, et al.
Journal of Hepatology|November 25, 2010
Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis BEric T T L Tjwa, Gertine W van Oord, Joost P Hegmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisFloris Dammeijer, Lysanne A Lievense, G D Marijn Veerman, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 28, 2011
[Exosomes and cancer]Jeroen de Vrij, S L Niek Maas, Joost P Hegmans, et al.
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Cancer Immunology Research|May 25, 2017
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC ImmunotherapyFloris Dammeijer, Lysanne A Lievense, Margaretha E Kaijen-Lambers, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Research|April 13, 2013
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancerJoachim G Aerts, Joost P Hegmans
BMC Pulmonary Medicine|December 14, 2012
Improving lung cancer survival; time to move onMarlies E Heuvers, Joost P Hegmans, Bruno H Stricker, et al.
Translational Lung Cancer Research|March 26, 2015
Immunotherapy prospects in the treatment of lung cancer and mesotheliomaJoachim G Aerts, Lysanne A Lievense, Henk C Hoogsteden, et al.
BMC Cancer|December 11, 2012
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatmentMarlies E Heuvers, Joachim G Aerts, Robin Cornelissen, et al.
Journal of Hepatology|November 25, 2010
Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis BEric T T L Tjwa, Gertine W van Oord, Joost P Hegmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisFloris Dammeijer, Lysanne A Lievense, G D Marijn Veerman, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 28, 2011
[Exosomes and cancer]Jeroen de Vrij, S L Niek Maas, Joost P Hegmans, et al.
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Cancer Immunology Research|May 25, 2017
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC ImmunotherapyFloris Dammeijer, Lysanne A Lievense, Margaretha E Kaijen-Lambers, et al.
Pageof 2